Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 365-370 , April 2010

Biodistribution and stability studies of [18F]Fluoroethylrhodamine B, a potential PET myocardial perfusion agent

  • Vijay Gottumukkala

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • Harvard Medical School, Boston, MA, USA
    • ,
  • Tobias K. Heinrich

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • Harvard Medical School, Boston, MA, USA
    • Current address: Molecular Imaging Research, Bayer Schering Pharma, Muellerstrasse 178, 13353 Berlin, Germany.
    • ,
  • Amanda Baker

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • ,
  • Patricia Dunning

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • ,
  • Frederic H. Fahey

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • Harvard Medical School, Boston, MA, USA
    • ,
  • S. Ted Treves

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • Harvard Medical School, Boston, MA, USA
    • ,
  • Alan B. Packard

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston, Boston, MA, USA
    • Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Division of Nuclear Medicine, Children's Hospital, Boston, MA 02115, USA. Tel.: +1 617 355 7539; fax: +1 617 730 0619.

Received 12 August 2009 ,Revised 10 December 2009 ,Accepted 11 December 2009.

References 

  1. Higuchi T, Bengel FM. Cardiovascular nuclear imaging: from perfusion to molecular function. Heart. 2008;94:809–816
  2. Beller GA, Watson DD. A welcomed new myocardial perfusion imaging agent for positron emission tomography. Circulation. 2009;119:2299–2301
  3. Studenov AR, Berridge MS. Synthesis and properties of 18F-labeled potential myocardial blood flow tracers. Nuc Med Biol. 2001;28:683–693
  4. Ravert HT, Madar I, Dannals RF. Radiosynthesis of 3-[18F]fluoropropyl and 4-[18F]fluorobenzyl triarylphosphonium ions. J Labelled Comp Radiopharm. 2004;47:469–476
  5. Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, et al. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med. 2006;47:1359–1366
  6. Madar I, Ravert H, DiPaula A, Du Y, Dannals RF, Becker L. Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med. 2007;48:1021–1030
  7. Madar I, Gao D, Ravert H, Chen L, Pomper M, Dannals R, et al. 18F-Fluorobenzyltriphenyl phosphonium PET detects area-specific apoptosis in the aging myocardium. In: Society of Nuclear Medicine, 54th Annual Meeting. Washington, DC. 2007;p. 166P
  8. Shoup TM, Elmaleh DR, Brownell A-L, Pitman JT, Zhu A, Wang X, et al. Evaluation of (4-[18F]fluorophenyl)triphenylphosphonium ion as a potential myocardial blood flow agent for PET. In: Society of Nuclear Medicine, 52nd Annual Meeting. Toronto, ON. 2005;p. 62P
  9. Marshall RC, Powers-Risius P, Reutter BW, O'Neil JP, La Belle M, Huesman RH, et al. Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl. J Nucl Med. 2004;45:1950–1959
  10. Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49:630–636
  11. Yalamanchili P, Wexler E, Hayes M, Yu M, Bozek J, Kagan M, et al. Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol. 2007;14:782–788
  12. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;14:789–798
  13. Purohit A, Radeke H, Azure M, Hanson K, Benetti R, Su F, et al. Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers. J Med Chem. 2008;51:2954–2970
  14. Heinrich TK, Treves ST, Packard AB. Development of 18F-labeled rhodamine B derivatives for myocardial perfusion imaging with PET. In: AMI/SMI Joint Molecular Imaging Conference. Providence, RI. 2007;
  15. Heinrich TK, Fahey F, Dunning P, Snay E, Treves ST, Packard AB. Synthesis and initial in vivo characterization of 18F-labeled rhodamine B: a potential PET myocardial perfusion agent. In: Society of Nuclear Medicine, 55th Annual Meeting. New Orleans, LA. 2008;p. 302P
  16. Heinrich TK, Gottumukkala V, Snay E, Dunning P, Fahey FH, Treves ST, et al. Synthesis of fluorine-18 labeled rhodamine B: a potential PET myocardial perfusion imaging agent. Appl Radiat Isot. 2010;68:96–100
  17. Gottumukkala V, Heinrich TK, Treves ST, Packard AB. Serum stability studies of F-18-ethyl-rhodamine B. J Labelled Comp Radiopharm. 2009;52(Suppl. 1):S110
  18. Lacerda SH, Abraham B, Stringfellow TC, Indig GL. Photophysical, photochemical, and tumor-selectivity properties of bromine derivatives of rhodamine-123. Photochem Photobiol. 2005;81:1430–1438
  19. Reungpatthanaphong P, Dechsupa S, Meesungnoen J, Loetchutinat C, Mankhetkorn S. Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. J Biochem Biophys Methods. 2003;57:1–16
  20. Hu Y, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol. 2000;60:1897–1905
  21. Lampidis TJ, Hasin Y, Weiss MJ, Chen LB. Selective killing of carcinoma cells “in vitro” by lipophilic-cationic compounds: a cellular basis. Biomed Pharmacother. 1985;39:220–226
  22. Rusiecka I, Skladanowski AC. Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids. Acta Biochim Pol. 2008;55:329–337
  23. De Moerloose B, Van de Wiele C, Dhooge C, Philippe J, Speleman F, Benoit Y, et al. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein. Eur J Nucl Med. 1999;26:396–403
  24. Vora MM, Dhalla M. In vivo studies of unlabeled and radioiodinated rhodamine-123. Nuc Med Biol. 1992;19:405–410
  25. Kronauge JF, Noska MA, Davison A, Holman BL, Jones AG. Interspecies variation in biodistribution of technetium (2-carbomethoxy- 2-isocyanopropane)6+. J Nucl Med. 1992;33:1357–1365
  26. Smart BE. Characteristics of C-F systems. In:  Banks RE,  Smart BE,  Tatlow JC editor. Organofluorine chemistry: principles and commercial applications. New York: Plenum Press; 1994;p. 68
  27. Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med. 2006;47:520–527
  28. Tewson TJ, Welch MJ. Preparation and preliminary biodistribution of “no carrier added” fluorine-18 fluoroethanol. J Nucl Med. 1980;21:559–564
  29. Harapanhalli RS, Roy AM, Adelstein SJ, Kassis AI. [125I/127I/131I]Iodorhodamine: Synthesis, cellular localization, and biodistribution in athymic mice bearing human tumor xenografts and comparison with [99mTc]hexakis(2-methoxyisobutylisonitrile). J Med Chem. 1998;41:2111–2117
  30. Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005;35:266–276
  31. López Arbeloa I, Ruiz Ojeda P. Dimeric states of rhodamine B. Chem Phys Lett. 1982;87:556–560
  32. Martarello L, Greenamyre JT, Goodman MM. Synthesis and evaluation of a new fluorine-18 labeled rotenoid as a potential PET probe of mitochondrial complex I activity. J Labelled Comp Radiopharm. 1999;42:1039–1051

PII: S0969-8051(09)00295-9

doi: 10.1016/j.nucmedbio.2009.12.005

Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 365-370 , April 2010

Article Tools

* Image Usage & Resolution